Is Pediatrix Medical Group (MD) Fully Priced As Q3 Earnings Tighten Guidance?

Q3 2026 earnings event puts Pediatrix Medical Group in focus

Pediatrix Medical Group (MD) is back on investors’ radar after its Q3 2026 report, with adjusted EBITDA of US$85 million and tighter full year guidance to a range of US$290 million to US$300 million.

Pediatrix Medical Group’s Q3 update lands after a strong run, with a 30 day share price return of 14.82% and a 90 day gain of 13.60%. The 1 year total shareholder return of 75.72% indicates that momentum has been building rather than fading.

Scan Pediatrix Medical Group’s momentum against other potential healthcare standouts by reviewing our curated 34 healthcare AI stocks with compelling growth stories and medical technology themes.

Momentum is clear after a 1 year total return of 75.72% and a recent Q3 beat, yet net income in the quarter moved lower year on year. Does the current Pediatrix Medical Group valuation still leave enough upside for new buyers?

Most Popular Narrative: 4.6% Overvalued

The most followed narrative pegs Pediatrix Medical Group’s fair value at $28.50, slightly below the recent $29.82 close. This frames the current momentum as rich rather than cheap and anchors expectations to a modest earnings trajectory and a discount rate of 7.24%.

Analysts are assuming Pediatrix Medical Group's revenue will grow by 4.0% annually over the next 3 years. Analysts assume that profit margins will shrink from 7.7% today to 7.4% in 3 years time.

See why 3 investors see Pediatrix Medical Group as 5% overvalued.

Result: Fair Value of $28.50 (OVERVALUED)

Still, portfolio restructuring, combined with a 7% revenue decline and rising salary pressures, could challenge Pediatrix Medical Group if payer negotiations or reimbursements soften.

Find out about the key risks to this Pediatrix Medical Group narrative.

Another View: Multiples Point To Good Value

The DCF fair value for Pediatrix Medical Group sits close to the current share price, yet the market is pricing the stock on a P/E of 15.1x versus a fair ratio of 20.6x and an industry average near 25x. That gap suggests investors might be pricing in extra risk. Or it may be leaving room for a future reset toward the fair ratio.

To stress test this P/E story against your own expectations, it is worth stepping through the valuation breakdown in more detail and then comparing Pediatrix Medical Group with other healthcare peers using similar metrics, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The debate around Pediatrix Medical Group is lively, so do not sit on the sidelines while others interpret the same figures for you. Take a few minutes to review the positive factors, and then weigh the 3 key rewards.

Looking for more Pediatrix Medical Group investment ideas?

If Pediatrix Medical Group has your attention, do not stop at one stock. Use this momentum to widen your watchlist with focused, data driven ideas that others may overlook.

• Target stability first and seek out companies with strong financial footing using the list of solid balance sheet and fundamentals (24 results).
• Hunt for quality at a sensible entry point by scanning the 33 high quality undervalued stocks that may offer more attractive pricing than current market favourites.
• Stack potential income on top of capital returns by reviewing the 5 dividend fortresses that emphasise higher yields with an eye on durability.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com